Factors associated with medical consumable availability in level 1 facilities in Malawi: a secondary analysis of a facility census.


Journal

The Lancet. Global health
ISSN: 2214-109X
Titre abrégé: Lancet Glob Health
Pays: England
ID NLM: 101613665

Informations de publication

Date de publication:
Jun 2024
Historique:
received: 19 04 2023
revised: 06 12 2023
accepted: 05 02 2024
medline: 19 5 2024
pubmed: 19 5 2024
entrez: 18 5 2024
Statut: ppublish

Résumé

Medical consumable stock-outs negatively affect health outcomes not only by impeding or delaying the effective delivery of services but also by discouraging patients from seeking care. Consequently, supply chain strengthening is being adopted as a key component of national health strategies. However, evidence on the factors associated with increased consumable availability is limited. In this study, we used the 2018-19 Harmonised Health Facility Assessment data from Malawi to identify the factors associated with the availability of consumables in level 1 facilities, ie, rural hospitals or health centres with a small number of beds and a sparsely equipped operating room for minor procedures. We estimate a multilevel logistic regression model with a binary outcome variable representing consumable availability (of 130 consumables across 940 facilities) and explanatory variables chosen based on current evidence. Further subgroup analyses are carried out to assess the presence of effect modification by level of care, facility ownership, and a categorisation of consumables by public health or disease programme, Malawi's Essential Medicine List classification, whether the consumable is a drug or not, and level of average national availability. Our results suggest that the following characteristics had a positive association with consumable availability-level 1b facilities or community hospitals had 64% (odds ratio [OR] 1·64, 95% CI 1·37-1·97) higher odds of consumable availability than level 1a facilities or health centres, Christian Health Association of Malawi and private-for-profit ownership had 63% (1·63, 1·40-1·89) and 49% (1·49, 1·24-1·80) higher odds respectively than government-owned facilities, the availability of a computer had 46% (1·46, 1·32-1·62) higher odds than in its absence, pharmacists managing drug orders had 85% (1·85, 1·40-2·44) higher odds than a drug store clerk, proximity to the corresponding regional administrative office (facilities greater than 75 km away had 21% lower odds [0·79, 0·63-0·98] than facilities within 10 km of the district health office), and having three drug order fulfilments in the 3 months before the survey had 14% (1·14, 1·02-1·27) higher odds than one fulfilment in 3 months. Further, consumables categorised as vital in Malawi's Essential Medicine List performed considerably better with 235% (OR 3·35, 95% CI 1·60-7·05) higher odds than other essential or non-essential consumables and drugs performed worse with 79% (0·21, 0·08-0·51) lower odds than other medical consumables in terms of availability across facilities. Our results provide evidence on the areas of intervention with potential to improve consumable availability. Further exploration of the health and resource consequences of the strategies discussed will be useful in guiding investments into supply chain strengthening. UK Research and Innovation as part of the Global Challenges Research Fund (Thanzi La Onse; reference MR/P028004/1), the Wellcome Trust (Thanzi La Mawa; reference 223120/Z/21/Z), the UK Medical Research Council, the UK Department for International Development, and the EU (reference MR/R015600/1).

Sections du résumé

BACKGROUND BACKGROUND
Medical consumable stock-outs negatively affect health outcomes not only by impeding or delaying the effective delivery of services but also by discouraging patients from seeking care. Consequently, supply chain strengthening is being adopted as a key component of national health strategies. However, evidence on the factors associated with increased consumable availability is limited.
METHODS METHODS
In this study, we used the 2018-19 Harmonised Health Facility Assessment data from Malawi to identify the factors associated with the availability of consumables in level 1 facilities, ie, rural hospitals or health centres with a small number of beds and a sparsely equipped operating room for minor procedures. We estimate a multilevel logistic regression model with a binary outcome variable representing consumable availability (of 130 consumables across 940 facilities) and explanatory variables chosen based on current evidence. Further subgroup analyses are carried out to assess the presence of effect modification by level of care, facility ownership, and a categorisation of consumables by public health or disease programme, Malawi's Essential Medicine List classification, whether the consumable is a drug or not, and level of average national availability.
FINDINGS RESULTS
Our results suggest that the following characteristics had a positive association with consumable availability-level 1b facilities or community hospitals had 64% (odds ratio [OR] 1·64, 95% CI 1·37-1·97) higher odds of consumable availability than level 1a facilities or health centres, Christian Health Association of Malawi and private-for-profit ownership had 63% (1·63, 1·40-1·89) and 49% (1·49, 1·24-1·80) higher odds respectively than government-owned facilities, the availability of a computer had 46% (1·46, 1·32-1·62) higher odds than in its absence, pharmacists managing drug orders had 85% (1·85, 1·40-2·44) higher odds than a drug store clerk, proximity to the corresponding regional administrative office (facilities greater than 75 km away had 21% lower odds [0·79, 0·63-0·98] than facilities within 10 km of the district health office), and having three drug order fulfilments in the 3 months before the survey had 14% (1·14, 1·02-1·27) higher odds than one fulfilment in 3 months. Further, consumables categorised as vital in Malawi's Essential Medicine List performed considerably better with 235% (OR 3·35, 95% CI 1·60-7·05) higher odds than other essential or non-essential consumables and drugs performed worse with 79% (0·21, 0·08-0·51) lower odds than other medical consumables in terms of availability across facilities.
INTERPRETATION CONCLUSIONS
Our results provide evidence on the areas of intervention with potential to improve consumable availability. Further exploration of the health and resource consequences of the strategies discussed will be useful in guiding investments into supply chain strengthening.
FUNDING BACKGROUND
UK Research and Innovation as part of the Global Challenges Research Fund (Thanzi La Onse; reference MR/P028004/1), the Wellcome Trust (Thanzi La Mawa; reference 223120/Z/21/Z), the UK Medical Research Council, the UK Department for International Development, and the EU (reference MR/R015600/1).

Identifiants

pubmed: 38762283
pii: S2214-109X(24)00095-0
doi: 10.1016/S2214-109X(24)00095-0
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1027-e1037

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Déclaration de conflit d'intérêts

Declaration of interests Besides funding from the Wellcome Trust and UK Research and Innovation going towards authors’ institutions, some authors took on private projects, outside the submitted work. SM declares receiving consulting fees from The Global Fund. TC declares consulting fees from the UN Economic Commission for Africa, and non-paid work chairing a Trial Steering Committee for a trial of adolescent mental health interventions in Nepal. ANP declares receiving consulting fees from the Bill & Melinda Gates Foundation. All other authors declare no competing interests.

Auteurs

Sakshi Mohan (S)

Centre for Health Economics, University of York, York, UK. Electronic address: sakshi.mohan@york.ac.uk.

Tara D Mangal (TD)

Department of Infectious Disease Epidemiology, Imperial College London, London, UK.

Tim Colbourn (T)

Institute for Global Health, University College London, London, UK.

Martin Chalkley (M)

Centre for Health Economics, University of York, York, UK.

Chikhulupiliro Chimwaza (C)

Department of Pharmaceuticals, Ministry of Health and Population, Lilongwe, Malawi.

Joseph H Collins (JH)

Institute for Global Health, University College London, London, UK.

Matthew M Graham (MM)

UCL Centre for Advanced Research Computing, University College London, London, UK.

Eva Janoušková (E)

Institute for Global Health, University College London, London, UK.

Britta Jewell (B)

Department of Infectious Disease Epidemiology, Imperial College London, London, UK.

Godfrey Kadewere (G)

Department of Pharmaceuticals, Ministry of Health and Population, Lilongwe, Malawi.

Ines Li Lin (I)

Institute for Global Health, University College London, London, UK.

Gerald Manthalu (G)

Department of Planning and Policy Development, Ministry of Health and Population, Lilongwe, Malawi.

Joseph Mfutso-Bengo (J)

School of Global and Public Health (SOGAPH), Kamuzu University of Health Sciences, Blantyre, Malawi.

Emmanuel Mnjowe (E)

Health Economics and Policy Unit, Kamuzu University of Health Sciences, Lilongwe, Malawi.

Margherita Molaro (M)

Department of Infectious Disease Epidemiology, Imperial College London, London, UK.

Dominic Nkhoma (D)

Health Economics and Policy Unit, Kamuzu University of Health Sciences, Lilongwe, Malawi.

Paul Revill (P)

Centre for Health Economics, University of York, York, UK.

Bingling She (B)

Department of Infectious Disease Epidemiology, Imperial College London, London, UK.

Robert Manning Smith (R)

Centre for Advanced Spatial Analysis, University College London, London, UK.

Wiktoria Tafesse (W)

Centre for Health Economics, University of York, York, UK.

Asif U Tamuri (AU)

UCL Centre for Advanced Research Computing, University College London, London, UK.

Pakwanja Twea (P)

Department of Planning and Policy Development, Ministry of Health and Population, Lilongwe, Malawi.

Andrew N Phillips (AN)

Institute for Global Health, University College London, London, UK.

Timothy B Hallett (TB)

Department of Infectious Disease Epidemiology, Imperial College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH